Herceptin

Oncology Therapeutics Making Big in Coming Years

Posted on Updated on

The industry’s 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche’s Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of the combined value of the 10 biggest-selling products.

Top 10 Oncology Drug Sales

Drug Name Company
Rituxan/MabThera Roche, Pharmstandard
Avastin Roche
Herceptin Roche
Gleevec  Novartis
Alimta Eli Lilly
Velcade Johnson & Johnson, Takeda,Pharmstandard
Erbitux Merck KGaA, Bristol-Myers Squibb
Lupron, Eligard AbbVie and Takeda; Sanofi   and Astellas Pharma
Zytiga Johnson & Johnson
Revlimid

Celgene, Pharmstandard

Rituxan is developed by Roche’s Genentech which is the first monoclonal antibody treatment for cancer. And even after 15 years on the market, it continues to see its sales grow, up 6% for Roche in 2013. The drug is also approved to treat a number of cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia (CLL), it also works against rheumatoid arthritis and generates about $1.2 billion a year in that category.

By comparing the sales of all the drugs the Roche company becomes the king of all the Pharmaceutical Companies involved in making oncology drugs.

Let’s have a look over the ranking on the basis of oncology sales 2013.

Top 10 Best Selling Oncology Drug Companies

Roche has topped the ranking by its top selling drugs, followed by Amgen, Novartis, Celgene, Johnson and Johnson, Lily, Astrazeneca, Merck, BMS and Takeda.